ClinicalTrials.gg
CompletedNCT02482155Updated Jun 26, 2015

Ibuprofen (MOMENT ACT ANALGESIC Granules) Pharmacokinetic Study

A Phase 1 interventional study of Ibuprofen in Healthy, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-26.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study was to evaluate the pharmacokinetic (PK) profile of ibuprofen after oral administration of a single dose of MOMENT ACT ANALGESIC granules to healthy male and female subjects, under fasting conditions.

02

Conditions studied

  • Healthy

Keywords

  • pharmacokinetics
  • MOMENTACT
  • ibuprofen 400 mg
  • oral
  • granules
03

In context

Lead sponsor

Aziende Chimiche Riunite Angelini Francesco S.p.A is the lead sponsor of 40 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : signed written informed consent before inclusion in the study;
  2. Sex and age: females and males, 18-55 years old both inclusive;
  3. (BMI): 18.5-30 kg/m2 inclusive;
  4. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the sitting position;
  5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study;
  6. and fertility (females only): females of must be using at least one of the following reliable methods of contraception:

    1. hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit;
    2. a non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit;
    3. a male sexual partner who agrees to use a male condom with spermicide;
    4. a sterile sexual partner. Female participants of non-child-bearing potential or in status for at least 1 year will be admitted. For all female subjects, pregnancy test result must be negative at screening and day -1.

Exclusion criteria

Exclusion Criteria:

  1. (ECG) 12-leads (supine position): abnormalities;
  2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study;
  3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness;
  4. Allergy: ascertained or presumptive to the active principle and/or formulations' ingredients or related drugs, namely non-steroidal anti-inflammatory agents (NSAIDs); history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study;
  5. Diseases: history of significant renal, hepatic, gastrointestinal (in particular gastroduodenal ulcer and bleeding), cardiovascular, respiratory (in particular asthma), skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study;
  6. Medications: medications, including over the counter (OTC) medications and herbal products for 2 weeks before the start of the study, in particular ibuprofen. Hormonal for females are allowed;
  7. Investigative drug studies: participation in the evaluation of any product in the 3 months before this study, calculated from the first day of the month following the last visit of the previous study;
  8. Blood donation: blood donations in the 3 months before this study;
  9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to United States Department of Agriculture Dietary Guidelines 2010], caffeine (>5 cups coffee/tea/day) or tobacco abuse (>=10 cigarettes/day); daily use of distilled spirits;
  10. Drug test: positive result at the drug test at screening or day-1;
  11. Alcohol test: positive alcohol breath test at day -1;
  12. Diet: abnormal diets (\<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study, vegetarians;
  13. Pregnancy (females only): positive or missing pregnancy test at screening or day -1, pregnant or lactating women.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ibuprofen

    ibuprofen 400 mg granules, oral solution, single administration under fasting conditions

    Drug: Ibuprofen

Interventions

  • ibuprofen 400 mg single dose oral solution

    Also known as: MOMENTACT

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of ibuprofen

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  2. Area under the plasma concentration versus time curve (AUC) of ibuprofen

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  3. Time to Cmax (Tmax) of ibuprofen

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  4. Apparent terminal elimination rate constant (λz) of ibuprofen

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  5. Apparent terminal elimination half-life (t1/2,z) of ibuprofen

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  6. Lag-time from the dosing time point prior to the first measurable plasma concentration (tlag) of ibuprofen

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  7. Time to the first ibuprofen plasma concentration of 5 ug/mL (ton5)

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

Secondary outcomes

  1. Time to the first ibuprofen plasma concentration of 10 ug/mL (ton10)

    Time frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose

  2. Occurrence of adverse effects

    Time frame: up to 24 hours after administration

07

Study locations

1 site
  • CROSS Research S.A., Phase I Unit, Via F.A. Giorgioli 14 Phone: Fax: +41.91.63.00.511 Email:
    Arzo, CH-6864, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 26, 2015
Start
Feb 2015
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Last update
Jun 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02482155
Collaborators
Cross Research S.A.
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Feb 2015
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Jun 26, 2015

Study contacts

Milko Radicioni, MD
principal investigator · Cross Research S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion